诺迪康品牌怎么样 申请店铺

我要投票 诺迪康在中草药行业中的票数:1223 更新时间:2026-01-27
诺迪康是哪个国家的品牌?「诺迪康」是 西藏诺迪康药业股份有限公司 旗下著名品牌。该品牌发源于西藏,由创始人陈达彬在1999-07-14期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。

外推网助力诺迪康品牌出海!将品牌入驻外推网,定制诺迪康品牌推广信息,可以显著提高诺迪康产品曝光,简直是跨境电商爆单神器!目前仅需1000元/年哦~

诺迪康怎么样

西藏诺迪康药业股份有限公司是西藏雪域高原上诞生的第一家高新技术制药上市企业,于1999年7月14日创立,1999年7月21日在上海证券交易所上网交易,股票名称:西藏药业,股票代码:600211。

在各级领导的关心和支持下,公司已经发展成为一家拥有员工4000余人,总资产8.2亿元的现代化制药企业。公司累计上缴税金2亿余元,发放员工工资、福利2.2亿余元;公司主要产品诺迪康胶囊年销售额逾亿元,公司生物一类新药重组人脑利钠肽也已经上市销售。

公司拥有西藏诺迪康医药有限公司、成都诺迪康生物制药有限公司、四川诺迪康威光制药有限公司、西藏康达药业有限公司、西藏诺迪康藏药材开发有限公司、四川本草堂药业有限公司等下属子公司。

公司秉承“科学成就健康,健康成就未来”的理念,以科技兴业。在为藏药现代化不遗余力的同时,公司注巨资于生物制品和传统药品的研发,并构建了林芝种植基地和四个生产基地及覆盖全国的营销网络。产品涵盖生物制品、藏药和中药、化学药的产品系列,奠定了西藏药业持续发展的基础,其中具有自主知识产权的生物制品一类新药新活素,代表着目前国际急性心衰急救治疗药物的最高水平,填补了该领域的国内空白。

公司上市以来连续被西藏自治区认定为高新技术企业、西藏自治区农牧业龙头企业,2001年被国家科学技术部认定为国家火炬计划重点高新技术企业。2008年公司被科技部认定为创新型试点企业。公司图形商标(祥云图)经国家工商总局认定为中国驰名商标,公司产品诺迪康胶囊和十味蒂达胶囊被评为国家中药保护品种,同时,还被国家保密局、科学技术部评为秘密级国家秘密技术。

经过多年来的不懈努力,公司已成为拥有一个国家级企业技术中心、四个符合GMP规范的药品生产基地、一个符合GAP藏药材种植基地及覆盖全国的营销网络,集藏药产品、植物药产品、化学药产品、生物制品研发、生产和销售一体的现代化企业。

Tibet nordikang Pharmaceutical Co., Ltd. is the first high-tech pharmaceutical listed enterprise born on the snow capped plateau of Tibet. It was founded on July 14, 1999 and traded on the Internet at Shanghai Stock Exchange on July 21, 1999. Its stock name is Tibet pharmaceutical, and its stock code is 600211. With the concern and support of leaders at all levels, the company has developed into a modern pharmaceutical enterprise with more than 4000 employees and total assets of 820 million yuan. The company has paid taxes of more than 200 million yuan and paid employees salaries and welfare of more than 220 million yuan; the annual sales volume of the company's main product, nordicon capsule, is more than 100 million yuan, and the company's new biological class I recombinant human brain natriuretic peptide has also been listed for sale. The company has subsidiaries including Tibet nordikang Pharmaceutical Co., Ltd., Chengdu nordikang biopharmaceutical Co., Ltd., Sichuan nordikang Weiguang Pharmaceutical Co., Ltd., Tibet Kangda Pharmaceutical Co., Ltd., Tibet nordikang Tibetan Medicine Development Co., Ltd., Sichuan bencaotang Pharmaceutical Co., Ltd. The company adheres to the concept of "science makes health, health makes future", and prospers with science and technology. While sparing no effort for the modernization of Tibetan medicine, the company has invested heavily in the research and development of biological products and traditional drugs, and has built the Linzhi planting base, four production bases and a nationwide marketing network. The products range from biological products, Tibetan medicine, traditional Chinese medicine and chemical medicine, laying the foundation for the sustainable development of Tibetan pharmaceutical industry, among which the biological products with independent intellectual property rights represent the highest level of international emergency treatment drugs for acute heart failure, and fill the domestic gap in this field. Since its listing, the company has been successively recognized as a high-tech enterprise in Tibet Autonomous Region, a leading enterprise in agriculture and animal husbandry in Tibet Autonomous Region, and a key high-tech enterprise in the national torch plan by the Ministry of science and technology of the people's Republic of China in 2001. In 2008, the company was recognized as an innovative pilot enterprise by the Ministry of science and technology. The company's graphic trademark (xiangyuntu) has been recognized as a well-known trademark in China by the State Administration of industry and commerce. The company's products, nordikang capsule and Shiweidida capsule, have been rated as the national traditional Chinese medicine protected varieties. Meanwhile, they have also been rated as the secret level national secret technology by the State Security Bureau and the Ministry of science and technology. After years of unremitting efforts, the company has become a modern enterprise with a national enterprise technology center, four GMP compliant pharmaceutical production bases, a gap compliant Tibetan medicine planting base and a nationwide marketing network, which integrates the research and development, production and sales of Tibetan medicine products, botanical medicine products, chemical medicine products and biological products.

本文链接: https://brand.waitui.com/0b45a7af1.html 联系电话:请联系客服添加 联系邮箱:请联系客服添加

外推网广告位招租,每天只要9块9

7×24h 快讯

阿迪达斯成为2026江苏省城市足球联赛官方战略合作伙伴

36氪获悉,1月27日,阿迪达斯宣布成为2026江苏省城市足球联赛官方战略合作伙伴。数据显示,联赛自2025年创立以来,整个赛季现场观赛人次累计突破243万,场均2.8万人的上座率创省级联赛纪录。线上直播观看人次超22亿,社交平台相关话题播放量突破1000亿。

2小时前

张江集团、陆家嘴集团在上海成立人工智能创新小镇生态服务公司

36氪获悉,爱企查App显示,近日,上海张江人工智能创新小镇生态服务有限公司成立,法定代表人为陈衡,注册资本1亿元人民币,经营范围包括人工智能双创服务平台、会议及展览服务、组织文化艺术交流活动、科技中介服务等。股东信息显示,该公司由上海张江(集团)有限公司、上海陆家嘴(集团)有限公司共同持股。

2小时前

金盘科技:筹划发行H股并在香港联合交易所有限公司上市

36氪获悉,金盘科技公告,公司拟在境外发行股份(H股)并在香港联合交易所有限公司主板上市,公司董事会授权公司管理层启动本次H股上市的前期筹备工作,授权期限为自董事会审议通过之日起12个月内。公司计划与相关中介机构就本次H股上市的具体推进工作进行商讨,关于本次H股上市的细节尚未确定。

2小时前

帝尔激光:筹划发行H股股票并在香港联交所上市

36氪获悉,帝尔激光公告,公司正在筹划发行境外上市外资股(H股)股票并申请在香港联合交易所有限公司主板挂牌上市,以推进国际化战略布局,打造多元化资本运作平台,提升国际品牌形象及全球市场综合竞争力,加快海外业务发展。相关细节尚未确定,本次发行H股并上市不会导致公司控股股东和实际控制人发生变化。该事项尚需提交公司董事会和股东会审议,并需取得相关监管机构备案、批准或核准。

2小时前

中国移动遭南向资金净卖出11.47亿港元

南向资金今日净卖出6.35亿港元,中国移动、紫金矿业、中芯国际分别遭净卖出11.47亿港元、8.43亿港元、5.53亿港元。净买入方面,腾讯控股、中国人寿、长飞光纤光缆净买入额位列前三,分别获净买入10.24亿港元、5.11亿港元、3.55亿港元。(第一财经)

2小时前

本页详细列出关于诺迪康的品牌信息,含品牌所属公司介绍,诺迪康所处行业的品牌地位及优势。
咨询